Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOS | P01100 | 2/20 | 0.54 |
| ▸ | JUN | P05412 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | PPARD | Q03181 | 2/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4289733 | 0.94 | FOS (0.48) | FOSJUNMEN1KMT2ALMNA | |
| SCHEMBL4284432 | 0.86 | HPGD (0.49) | FOSJUNMEN1KMT2ALMNA | |
| SCHEMBL4284962 | 0.86 | MAPK1 (0.50) | FOSJUNMEN1KMT2ALMNA | |
| SCHEMBL4279676 | 0.84 | FOS (0.52) | FOSJUNMEN1KMT2ALMNA | |
| SCHEMBL4289803 | 0.84 | FOS (0.54) | FOSJUNLMNANPC1ADRB1 | |
| SCHEMBL4279716 | 0.83 | FOS (0.63) | FOSJUNPOLBNPC1MAPT | |
| SCHEMBL4286099 | 0.83 | FOS (0.52) | FOSJUNMEN1KMT2ALMNA | |
| SCHEMBL4283765 | 0.82 | FOS (0.50) | FOSJUNLMNAPOLBTP53 | |
| SCHEMBL4276620 | 0.81 | JUN (0.81) | FOSJUNPPARDFFAR1NPC1 | |
| SCHEMBL4289725 | 0.81 | HPGD (0.44) | FOSJUNKMT2ALMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118169-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL USE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-05-07 | — | — | US | disclosed |
| US-7314888-B1 | Compounds and medicinal use thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-01-01 | — | — | US | disclosed |
| EP-1127869-A1 | NOVEL COMPOUNDS AND MEDICINAL USE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2001-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118169-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL USE THEREOF | SP1, AP1G1, AP1M1 | FOS 63/4885JUN 20/4885MEN1 2341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.